This continuing medical education (CME) activity will provide highlights from 2 Live Grand Round Sessions, offering expert insights on key concepts in immunotherapy for advanced NSCLC. Core topics include the rationale for immunotherapy, the critical importance of guideline-driven biomarker testing in patient selection, and the most current data on checkpoint inhibitor monotherapies, combinations, and emerging regimens.
This activity is intended for oncology, pathology, and pulmonology clinicians (MD/DO/NP/PA) engaged in the care of patients with non-small cell lung cancer (NSCLC).
Completion of the course will help you:
Identify patients with advanced NSCLC eligible for frontline immunotherapy using biomarker test results
Apply efficacy and safety data on frontline immunotherapy when treating patients with advanced NSCLC